In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...